AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$KYMR

Booth Bruce sold $56.5M of KYMR (indirect holdings)

Booth Bruce sold 513,245 indirectly-held shares of Kymera Therapeutics, Inc. (KYMR) at an average of $110.01 ($105.78–$118.66, $56.46M total) across 30 trades over 2026-06-26 to 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Booth Bruce
Published Jun 30, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KYMR
Neutral
medium confidence
Mentioned
$KYMR
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KYMRNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider selling size and timing, but it does not include new operational/clinical/regulatory information about Kymera Therapeutics.

02

Market read

A $56.46M director sale under 10b5-1 is a sentiment datapoint, but it is unlikely to be a standalone fundamental catalyst.

03

What to watch

Traders may over-weight insider selling; the key incremental signal is whether there are additional filings (other insiders, new grants, or company-specific catalysts) around the same period.

Relevance 7/10Novelty 5/10Timing: Filed June 30 after sales executed June 26–29

Background

SEC Form 4 reports an insider transaction by Kymera Therapeutics director Booth Bruce, with ownership form listed as indirect and executed under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$KYMRNeutralMedium confidence
Context

Kymera Therapeutics director Booth Bruce sold $56.46M of KYMR via an open-market sale under a pre-arranged 10b5-1 plan (513,245 shares).

Expected impact

Likely limited, short-lived sentiment impact; follow-through depends on broader fundamentals and any concurrent company news.

Evidence & confidence

Form 4 discloses a sizable sale ($56.46M) and confirms it was pre-arranged (10b5-1), which typically reduces the signal of new negative information.

Market effects

Sector

No direct sector read-across; this is company-specific insider transaction disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale was under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than a change in outlook.

Key entities

  • issuer
    Kymera Therapeutics, Inc.

    Subject of the Form 4 insider transaction; director Booth Bruce sold shares under a 10b5-1 plan.

  • insider
    Booth Bruce

    Director who executed the open-market sale of KYMR shares (indirect holdings).

  • trading mechanism
    Rule 10b5-1 plan

    Pre-arranged plan cited in the filing, typically reducing interpretive weight of the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KYMR insider trading history →

Related articles

$KYMRMed

Kymera (KYMR) Q3 2026 Earnings Call Transcript

Kymera (KYMR) reported Q3 2026 earnings, highlighting progress in its pipeline, including Phase IIb data for KT-621 in atopic dermatitis (AD) expected by year-end. The BROADEN 2 study's placebo-controlled portion is complete, with 98% of eligible patients enrolling in the open-label extension. The company also discussed market research indicating a demand for safe, effective oral treatments for AD.

finance.yahoo.com
$KYMRMed

Kymera Therapeutics Q3 Earnings Call Highlights

Kymera Therapeutics reported Q3 results, highlighting 98% inhibition of TLR7/8-stimulated interferon-beta levels and positive phase I data for KT-579. The company plans a phase Ib lupus study (LUMORA) in early 2027. KT-621 is expected to show atopic dermatitis efficacy comparable to dupilumab. Q3 R&D expenses were $128.5M, with cash position of $1.6B providing runway into 2029.

finance.yahoo.com
$KYMRMedAI 8/10

Kymera Q3 2026 slides: IRF5 degrader shows 90%+ target engagement

Kymera Therapeutics (KYMR) reported Q3 2026 results, missing earnings but showing 90%+ target engagement for its IRF5 degrader KT-579. The stock rose 3.46% premarket. The company reported a net loss of $132M, up from $82.2M YoY, with R&D expenses increasing 73%. Kymera has $1.6B in cash, providing a runway into 2029. KT-579 showed promising Phase 1 data, with significant biomarker reductions and a favorable safety profile.

investing.com
$KYMRHigh

Kymera Therapeutics 3Q 2026: Revenue $0 Net loss $132M, EPS $(1.32) — 10-Q Summary

Kymera Therapeutics reported 3Q 2026 revenue of $0, down from $2.8M a year earlier, and a net loss of $132M, or $(1.32) per share, compared to a net loss of $82.2M, or $(0.94) per share, in the prior-year quarter. The company's collaboration revenue for the nine months increased to $99.4M, driven by partnerships with Gilead and Sanofi. Research and development spending rose 49%, primarily due to expanded program work and personnel investments.

tradingview.com
$KYMRHighAI 8/10

Kymera reports phase 1 data for KT-579, plans lupus trial

Kymera Therapeutics (KYMR) reported phase 1 trial results for KT-579, showing significant IRF5 degradation and biomarker reductions. The company plans a phase 1b lupus trial in 2027. Q3 2026 net loss was $132.0M, up from $82.2M in 2025, with R&D expenses increasing. Cash reserves are $1.6B, expected to last into 2029. Updates on other clinical trials were also provided.

investing.com